Pfizer Leaps Into Japanese Generics Foray; Aims For 100 Generic Products By 2011
This article was originally published in PharmAsia News
Executive Summary
Pfizer's Established Products Business Unit, a branch in charge of invigorating off-patent drugs and leading generic drug activities, will establish commercial operations in Japan starting Dec. 1
You may also be interested in...
Pfizer, Wyeth Japan Subsidiaries Merge To Become Second-largest Pharma
TOKYO - Pfizer Japan and Wyeth Japan, both of them fully owned by their U.S. parent firms, announced their merger, effective June 1, becoming Japan's second-largest pharmaceutical manufacturer after Takeda Pharmaceutical Co. and expanding Pfizer Japan's cardio and neural product lineup with Wyeth's vaccines
Pfizer, Wyeth Japan Subsidiaries Merge To Become Second-largest Pharma
TOKYO - Pfizer Japan and Wyeth Japan, both of them fully owned by their U.S. parent firms, announced their merger, effective June 1, becoming Japan's second-largest pharmaceutical manufacturer after Takeda Pharmaceutical Co. and expanding Pfizer Japan's cardio and neural product lineup with Wyeth's vaccines
Daiichi Sankyo Generics Entry Could Help Japan's Branded Generics Makers
Following Pfizer's step, Daiichi Sankyo is venturing into the generic drug business in Japan. The third-largest domestic branded drug maker Feb. 26 announced the establishment of generic subsidiary Daiichi Sankyo Espha, and a plan to start marketing products beginning in October. The announcement has stirred up a shock wave across the industry